Flags

Earnings warning

OmniAb

NMQ:OABI · US68218J1034

Life Sciences Tools & ServicesSmall

360

Value38

Profit price71

Cash yield1

Owner Earnings Yield1

Dividend Yield1

Sales & asset price33

Price/Sales5

EV / Gross Profit28

Price/Book67

Quality35

Returns on capital38

Return on Capital28

Cash Return on Capital44

Return on Equity42

Profit margins13

EBIT Margin4

Gross Profitability22

Cash backing39

Accruals67

Owner Earnings Margin10

Growth67

Sales growth98

Profit growth18

Reinvestment100

Price momentum79

Safety65

Debt load89

Debt serviceability16

Refinancing31

Debt Payback1

Liquidity87

Sentiment56

Analyst ratings100

Expectations trend73

Opinion Changes50

Price Target Upside96

Market mood17

Value Creation10/20creating some value

Creates more value than its capital costs
Owner earnings growing
Owner earnings per share growing
Reinvests at strong returns
Solid earnings base

What this means

OmniAb clears its cost of capital, but the record is mixed across the five tests. Real value creation, just not yet consistent.

Profile

CountryUSA

IndustryLife Sciences Tools & Services

SizeSmall

TypePublic Company

ExchangeNASDAQGM

Founded2021

Employees63

Websiteomniab.com

ISINUS68218J1034

Last UpdateApr 2, 2026

Indices

NASDAQ (USA)

Themes

Machine LearningImmunologyArtificial IntelligenceGeneticsBiomedical EngineeringBiotechnologyInformation Technology

Description

OmniAb, Inc. (OmniAb) licenses cutting-edge discovery research technology to pharmaceutical and biotech companies and academic institutions to enable the discovery of next-generation therapeutics. The company’s technology platform creates and screen…

Analysis

Middle-of-the-road

OmniAb, Inc. is a middle-of-the-road business: neither the economics nor the price stand out from the peer group.

Valuation data is not available for this company.

The trajectory is solid and the balance sheet is sturdy. The company scores 10/20 on our value-creation score: creating some value.

Nothing is flagged here: no red or amber gates, no divergence between profits and cash. That is itself information: the numbers are straightforward. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250

2026

All-time high

Mar 2026

All-time low

Jun 2026

Average rank

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023

Price/Sales

—

Price/Earnings

—

Price/Book

—

Dividend Yield

—

Value (overall)

—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare OmniAb with its peers

Azenta

NSQ:AZTA

CountryUSA

IndustryLife Sciences Tools & Services

SizeMedium

Full Stock Analysis →

AbCellera Biologics

NSQ:ABCL

CountryCanada

IndustryLife Sciences Tools & Services

SizeSmall

Full Stock Analysis →

Lantheus

NMQ:LNTH

CountryUSA

IndustryHealth Care Equipment & Supplies

SizeLarge

Full Stock Analysis →

Tempus AI

NSQ:TEM

CountryUSA

IndustryLife Sciences Tools & Services

SizeMedium

Full Stock Analysis →

Bionano Genomics

NAQ:BNGO

CountryUSA

IndustryLife Sciences Tools & Services

SizeSmall

Full Stock Analysis →

Inotiv

NAQ:NOTV

CountryUSA

IndustryLife Sciences Tools & Services

SizeSmall

Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View

1 · Watch OutGood· 100

Value

1 · ExpensiveGood Value· 100

Quality

1 · Weak FundamentalsHigh Quality· 100

Growth

1 · Tough TimesHigh Growth· 100

Safety

1 · High LeverageWell-Financed· 100

Sentiment

1 · SkepticismPositive· 100

Learn More →